SKYE vs WKSP Comparison

Skye Bioscience Inc is a pre-clinical pharmaceutical company located in San Diego, California. The company's clinical assets focus on the modulation of cannabinoid receptor 1 ("CB1") to provide novel treatments and alternatives for diseases caused by metabolic disorders, inflammation, fibrosis, and neurodegeneration, such as obesity and glaucoma. The company's Phase 2 clinical candidates include nimacimab, a negative allosteric modulating antibody that inhibits peripheral CB1 receptors, currently being developed for the treatment of obesity and SBI-100 Ophthalmic Emulsion ("SBI-100 OE"), a CB1 agonist (activator), currently being developed for the treatment of glaucoma and ocular hypertension.

Worksport Ltd designs, develops, and manufactures products for markets including automotive accessories, consumer electronics, and residential and commercial HVAC systems. The company leverages a growing intellectual property portfolio of patents, designs, and trademarks covering products such as tonneau covers, solar-integrated tonneau covers, portable power stations, hydrogen-based green energy systems, heat pumps, and EV charging solutions. Its segments include soft tonneau covers, consisting mainly of vinyl-wrapped tri-fold and quad-fold covers manufactured by third-party suppliers, and hard tonneau covers, which generate the majority of revenue in the United States and include aluminum tri-fold and quad-fold covers manufactured and assembled in the United States.